Use this url to cite publication: https://hdl.handle.net/20.500.12512/116211
Options
Blood Protein Profile for Astrocytoma Diagnosis and Prognosis / Rūta Urbanavičiūtė, Daina Skiriutė
Type of publication
Tezės kitame recenzuojamame leidinyje / Theses in other peer-reviewed publication (T1e)
Title
Blood Protein Profile for Astrocytoma Diagnosis and Prognosis / Rūta Urbanavičiūtė, Daina Skiriutė
Publisher (trusted)
Vilnius University Press |
Date Issued
Date Issued |
---|
2022-11-25 |
Extent
p. 53-53.
Is part of
14th International Conference of the Lithuanian Neuroscience Association : 25 November 2022, Vilnius, Lithuania : Abstract book / Lithuanian Neuroscience Association. Vilnius University. Vilnius : Vilnius University Press, 2022. ISBN 9786090707968.
Version
Originalus / Original
Description
no. P38
Poster presentations
ISBN 978-609-07-0796-8
Field of Science
Abstract
Relative five-year survival for brain cancers has hardly changed in 30 years, increasing by 1%, when in all cancers combined, it increased nearly 20%. The most frequent group of primary brain tumours, astrocytomas, and especially glioblastoma (GBM), is very aggressive. In adult GBM group 1-year and 5-years relative survival is 41% and 5%. The treatment of astrocytoma is complicated due to the absence of reliable tools, which would allow monitoring of essential aspects of tumorigenesis. Present study aimed to find profiles of circulating blood serum proteins, specific for astrocytomas, in order to track cancerous processes in brain tissue. Study consisted of two parts - selection and validation studies. In the first part, 79 different grade astrocytoma patients’ tumour tissue and serum samples were analysed. For the validation study - 162 independent serum samples were used. In the part one, ten blood circulating markers were evaluated using multiplexing antibody array technology in blood samples of astrocytoma patients and healthy participants. Profile, consisting of four proteins - ANGPT1, IP-10, TIMP-1 and TGF-β1, was identified as the most promising for astrocytomas diagnostic. With the same sample set, patients’ survival prediction tool (Patients Survival Score) was created, and 2-years survival was predicted with the accuracy of 83.8%. It consisted of two molecular variables - values of CHI3L1 and OPN expression in serum, together with patient’s IDH1 mutational status. With different sample set, second part of the investigation was performed and improved diagnostic serum profile for astrocytomas was revealed, consisting of TGF-β1, TIMP-1 and CHI3L1 protein values. The accuracy of calculated PSS was also confirmed.
Type of document
type::text::conference output::conference proceedings::conference paper
ISBN (of the container)
9786090707968
Other Identifier(s)
(LSMU ALMA)991680983407106
Coverage Spatial
Lietuva / Lithuania (LT)
Language
Anglų / English (en)